ArriVent BioPharma, Inc. — Investor Relations & Filings
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy involves forging strategic collaborations to in-license and advance promising drug candidates for global patient populations. Its lead development candidate is firmonertinib, a novel therapeutic for cancer. ArriVent's pipeline also includes other oncology therapeutics, such as next-generation antibody drug conjugates. The company leverages its team's extensive drug development and regulatory experience to design development strategies with clear paths to approval, aiming to address significant unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 4 Filing | 2026-02-04 | English | |
| 4 Filing | 2026-02-04 | English | |
| 4 Filing | 2026-02-04 | English | |
| 4 Filing | 2026-02-04 | English | |
| 4 Filing | 2026-02-04 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 32132559 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32132554 | 4 Filing | 2026-02-04 | English | ||
| 32132552 | 4 Filing | 2026-02-04 | English | ||
| 32132551 | 4 Filing | 2026-02-04 | English | ||
| 32132541 | 4 Filing | 2026-02-04 | English | ||
| 32132535 | 4 Filing | 2026-02-04 | English | ||
| 32132566 | 4 Filing | 2026-02-03 | English | ||
| 32132539 | SCHEDULE 13G/A Filing | 2026-01-30 | English | ||
| 13482406 | Major Shareholding Notification 2026 | 2026-01-21 | English | ||
|
2025
6 filings
| |||||
| 13482410 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13482450 | 10-Q | 2025-11-10 | English | ||
| 13482457 | 8-K | 2025-11-10 | English | ||
| 13482461 | Major Shareholding Notification 2025 | 2025-11-05 | English | ||
| 13482471 | Major Shareholding Notification 2025 | 2025-10-30 | English | ||
| 13482465 | Major Shareholding Notification 2025 | 2025-10-18 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ajanta Pharma Ltd.
Specialty pharmaceutical firm focused on complex generics a…
|
AJANTPHARM | IN | Manufacturing |
|
Akari Therapeutics Plc
Develops next-gen antibody-drug conjugates using proprietar…
|
AKTX | US | Manufacturing |
|
Akebia Therapeutics, Inc.
A biopharmaceutical company that develops and commercialize…
|
AKBA | US | Manufacturing |
|
Akeso, Inc.
Global commercial-stage biopharma developing innovative ant…
|
9926 | KY | Manufacturing |
|
Aktis Oncology, Inc.
A clinical-stage biotech developing targeted alpha radiopha…
|
AKTS | US | Manufacturing |
|
Akums Drugs and Pharmaceuticals Limited
CDMO providing end-to-end pharmaceutical manufacturing and …
|
AKUMS | IN | Manufacturing |
|
Albert David Ltd.
Produces pharmaceutical formulations, infusions, and specia…
|
ALBERTDAVD | IN | Manufacturing |
|
Aldeyra Therapeutics, Inc.
Develops medications for immune-mediated ocular and systemi…
|
ALDX | US | Manufacturing |
|
Aleafia Health Inc.
Vertically integrated cannabis company with cultivation, pr…
|
AH | CA | Manufacturing |
|
Alector, Inc.
Clinical-stage biotech using immuno-neurology to treat neur…
|
ALEC | US | Manufacturing |
ArriVent BioPharma, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32470/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32470 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32470 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32470 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32470}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ArriVent BioPharma, Inc. (id: 32470)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.